Both EurrekAlert
and News
Medical published the following article on misfolding diseases including
Kennedy’s Disease (SBMA). It is good to see more attention focused on this
condition.
Protein misfolding diseases, such as Alzheimer's and Parkinson's Disease, are rising in incidence and seeing increasing financial and healthcare burden. Treatments and accurate diagnostics for these diseases are lacking.
This issue of Future Science OA, featuring Guest
Editor Salvador Ventura (Universitat Autònoma de Barcelona, Spain), highlights
recent advances in the understanding of these disorders, and provides fresh
ideas for their future therapy. In a series of articles written by experts at
the cutting edge of the field, the issue begins by looking at recent inroads
into our expanding knowledge of protein misfolding disorders and their protein
targets. It then goes on to look at amyloid aggregation in specific disease
areas, including the neurodegenerative: Alzheimer's, Parkinson's and
Huntingdon's disease; glioblastoma; cystic fibrosis; spinal and bulbar muscular atrophy; and malaria. …”
__________
Also, eLife
published the abstract of a recent study of Kennedy’s Disease. I understood some of the article, but am hoping
Ed Meyertholen will provide some needed clarification on this research.
Abstract
“Spinal and Bulbar Muscular Atrophy (SBMA) is a progressive
neuromuscular disease caused by polyglutamine expansion in the Androgen
Receptor (AR) protein. Despite extensive research, the exact pathogenic
mechanisms underlying SBMA remain elusive. Here we present evidence that
Nemo-Like Kinase (NLK) promotes disease pathogenesis across multiple SBMA model
systems. Most remarkably, loss of one copy of Nlk rescues SBMA
phenotypes in mice, including extending lifespan. We also investigated the
molecular mechanisms by which NLK exerts its effects in SBMA. Specifically, we
have found that NLK can phosphorylate the mutant polyglutamine-expanded AR,
enhance its aggregation, and promote AR-dependent gene transcription by
regulating AR-cofactor interactions. Furthermore, NLK modulates the toxicity of
a mutant AR fragment via a mechanism that is independent of AR-mediated gene
transcription. Our findings uncover a crucial role for NLK in controlling SBMA
toxicity and reveal a novel avenue for therapy development in SBMA.”
Note: You can
download the PDF of the abstract near the top of the linked page.